All In Biotech

Drug Trial Radar · NCT07391813

SNB-101 for Treatment of Extensive Stage Small Cell Lung Cancer

A Phase 1b/2, Open-Label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of SNB-101, in Extensive Stage Small Cell Lung Cancer.

Last checked: Nov 19, 2026Latest source record: Mar 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

55

Planned (sponsor's estimate)

Start

Mar 2026

Primary completion

Dec 2028

Study completion Dec 2028

Sponsor

Lead sponsor
SN BioScienceIndustry
Sponsor type
Industry
First posted
Feb 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the Phase 1 research is to test the safety, tolerability, maximum tolerated dose, and pharmacokinetics (PK- the study of how a medicine moves through subject body. It looks at how the drug is absorbed, travels in your blood, reaches different parts of subject body, and is eventually broken down and removed) of the SNB-101.The Phase 2 is to determine the optimal dose (amount of medicine that works best to treat a condition while causing the fewest side effects) of SNB-101 for further research and to collect a further information on PK, safety and tolerability. Once subject has completed assessments during screening and if subject is found eligible to participate in the study, study drug will be given by intravenous infusion on day 1 and day 15 of each cycle treatment. Throughout the treatment period, the study doctor will monitor subject for any changes to subject health. While subject is taking the study drug, we will ask subject the following: * How subject are feeling. * If subject has experienced any side effects. * If subject is taking other medications or if there are changes to the medications subject was taking before. The study drug will be taken over multiple cycles. A cycle is the time between the start of 1 round of treatment until the start of the next round. In this study, each treatment cycle is of 28 days.

Conditions

  • Patient is Not Suitable for Complete Surgical Resection With a Cytologically or Histologically Confirmed Small Cell Lung Cancer(SCLC)

Interventions

  • SNB-101Drug

    SNB-101 is a nanoparticle formulation of SN-38 administered intravenously. Subject enrolled for each dose level cohort of 50/80 mg/m2, 60/96 mg/m² and 70/112 mg/m2 will be administered intravenously over 90 minutes at Day 1 and Day 15 of each cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Limiting Toxicity (DLT) according to CTCAE version 5.0 in Phase 1Time frame: Dose limiting toxicities will be evaluated during the first treatment cycle (28 days)
  2. Treatment discontinuation/dose reduction due to Adverse Events (AEs) in Phase 1Time frame: Day 1 through study completion, an average of 2 years
  3. Number of Adverse Events (AE) that occurs in Phase 1Number of Adverse Events (AE) that occurs in Phase 1Time frame: Adverse events will be recorded from informed consent through 28 days (±7 days) after the last dose of study drug
  4. Laboratory Parameters in Phase 1Time frame: For hematology, clinical chemistry and coagulation: at Screening; at Days 1, 8, 15, and 22 of Cycle 1; at Days 1 and 15 of each subsequent treatment cycle (each cycle is 28 days); and at End of Treatment (EOT) For urinanalysis: at screening, day 1 of cy
  5. Vital Signs in Phase 1Time frame: Baseline through study completion, an average of 2 years
  6. ECG Parameters in Phase 1Time frame: On Day 1 of cycle 1, cycle 2, cycle 3 and cycle 4. (Each cycle is 28 days)
  7. Chest X-ray (CXR) Abnormalities in Phase 1Time frame: Baseline (Screening) through study completion, an average of 2 years
  8. Optimized Dose of SNB-101 in Phase 2Time frame: Day 1 through study completion, an average of 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Institute for Pulmonary Diseases of Vojvodina

    Kamenitz, Serbia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.